Pharma largely dominates research spending in Switzerland

The pandemic will not have prevented companies from investing in research and development (R&D) in Switzerland. In 2021, the amount of these investments reached 16.8 billion francs, propelled by spending by the pharmaceutical industry; 1.3 billion more than in 2019, the date of the last survey carried out by the Federal Statistical Office (FSO), were therefore spent. This increase represents an average annual increase in expenditure of 4.1% compared to 2019.